Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Inventory (2016 - 2025)

Historic Inventory for Fortress Biotech (FBIO) over the last 10 years, with Q3 2025 value amounting to $12.6 million.

  • Fortress Biotech's Inventory rose 668.48% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year increase of 668.48%. This contributed to the annual value of $14.9 million for FY2024, which is 4642.37% up from last year.
  • Per Fortress Biotech's latest filing, its Inventory stood at $12.6 million for Q3 2025, which was up 668.48% from $13.6 million recorded in Q2 2025.
  • Fortress Biotech's 5-year Inventory high stood at $16.1 million for Q1 2022, and its period low was $2.3 million during Q1 2021.
  • In the last 5 years, Fortress Biotech's Inventory had a median value of $12.5 million in 2025 and averaged $12.2 million.
  • In the last 5 years, Fortress Biotech's Inventory soared by 108403.64% in 2021 and then tumbled by 2791.86% in 2023.
  • Quarter analysis of 5 years shows Fortress Biotech's Inventory stood at $9.9 million in 2021, then skyrocketed by 43.57% to $14.2 million in 2022, then decreased by 27.92% to $10.2 million in 2023, then skyrocketed by 46.42% to $14.9 million in 2024, then decreased by 15.85% to $12.6 million in 2025.
  • Its Inventory was $12.6 million in Q3 2025, compared to $13.6 million in Q2 2025 and $12.5 million in Q1 2025.